Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Valerie Takyi

Vascular Surgery Naperville, IL Medical Doctor

NPI 1316266976 CMS profile 1380436

1020 E Ogden Ave Ste 301, Ste 301, Naperville, IL 60563

Open in the dashboard

General payments

$7,185

62 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Valerie Takyi of Naperville, IL is reported in the CMS Open Payments database as having received $7,185 across 62 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 60th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $117 2
2024 General $1,291 6
2023 General $3,654 19
2022 General $286 6
2021 General $541 12
2020 General $348 3
2019 General $948 14

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Valerie Takyi
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Valerie Takyi were reported at $117. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Valerie Takyi Vascular Surgery median Middle half National median
2019 $948 $796 $226–$2,363 $163
2020 $348 $348 $118–$1,110 $114
2021 $541 $471 $158–$1,421 $132
2022 $286 $725 $222–$2,183 $149
2023 $3,654 $836 $257–$2,440 $160
2024 $1,291 $909 $252–$2,619 $164
2025 $117 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Penumbra, Inc. $2,823 7 payments
  2. Silk Road Medical, Inc. $1,621 10 payments
  3. Medtronic Vascular, Inc. $623 6 payments
  4. Cook Medical LLC $548 11 payments
  5. Medtronic, Inc. $487 7 payments
  6. Terumo Medical Corporation $371 2 payments
  7. Bard Peripheral Vascular, Inc. $313 6 payments
  8. Janssen Pharmaceuticals, Inc $104 5 payments
  9. Welch Allyn $89 1 payment
  10. Endologix, Inc. $64 1 payment
  11. Other $143 6 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,948 54 payments
  2. Travel and Lodging $2,798 6 payments
  3. Consulting Fee $350 1 payment
  4. Debt forgiveness $89 1 payment
Products named General payments · program years 2019–2025
  1. Indigo System $2,823 7 payments
  2. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $1,445 8 payments
  3. ENROUTE Transcarotid Stent $1,445 8 payments
  4. ENROUTE Transcarotid Neuroprotection System Cardiology/Vascular Diseases $1,203 5 payments
  5. ENROUTE Enflate Transcarotid RX Balloon Dilatation Catheter $1,203 5 payments
  6. Endurant $370 3 payments
  7. NAVICROSS $350 1 payment
  8. ENROUTE Transcarotid Neuroprotection System Carotid Artery Disease $176 2 payments
  9. ENROUTE Transcarotid Stent System $176 2 payments
  10. ENHANCE Transcarotid Peripheral Access Kit $176 2 payments
  11. Other $2,426 49 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 3 drugs

Part D claims

180

Median for Vascular Surgery: 122

Drug cost

$12,323

Median for Vascular Surgery: $14,135

Branded share of claims

71.1%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xarelto Rivaroxaban Brand 11 $10,238
Clopidogrel Clopidogrel Bisulfate Brand 117 $1,544
Atorvastatin Calcium Generic 52 $540

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 114 billing codes

Paid by Medicare

$287,957

Medicare's payments for the services billed

Medicare patients

788

Average age 76

Services billed

1,869

424 women, 364 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 47%
Arthritis 46%
Diabetes 36%
Chronic kidney disease 36%
Heart failure 28%
COPD 24%
Atrial fibrillation 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

62 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Illinois

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record